Physician profile
Michael B Cotter
NPI 1669492641
$1,363.49
in general payments reported to CMS, 2019-2025
32 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $40.00 · 2021: $338 · 2022: $300 · 2023: $202 · 2024: $152 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.38 | 2019-2025 | |
| Caldera Medical, INC | $91.24 | 2021 | |
| Coopersurgical, INC. | $84.71 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Myovant Sciences INC. | $75.63 | 2022 | |
| Organon LLC | $74.32 | 2021-2023 | |
| Hologic Sales and Service, LLC | $68.03 | 2023-2024 | Aptima, Acessa Provu System, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $65.08 | 2025 | |
| Astellas Pharma US INC | $49.92 | 2024 | Veozah |
| Lsi Solutions INC | $47.42 | 2023 | Fornisee |
| Minerva Surgical, INC | $35.71 | 2023 | |
| Dysis Medical, INC. | $35.30 | 2021 | |
| Exeltis, USA INC. | $33.34 | 2024-2025 | Slynd |
| Allergan, INC. | $31.36 | 2019 | |
| Boston Scientific Corporation | $31.02 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $29.60 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $25.69 | 2022 | |
| Ethicon US, LLC | $24.18 | 2023 | Harmonic, Enseal, Surgicel Nu-Knit |
| Shield Therapeutics INC | $19.72 | 2022 | |
| Covidien LP | $17.46 | 2020 | |
| Sumitomo Pharma America, INC. | $17.27 | 2025 | Myfembree |
| Innovation Technologies INC | $16.03 | 2025 | Irrisept |
| Millicent US INC | $15.48 | 2025 | Femring, Intrarosa |
| Medtronic, INC. | $14.37 | 2022 | |
| Merck Sharp & Dohme LLC | $14.37 | 2023 | Gardasil 9 |
| Olympus America INC. | $13.49 | 2022 | |
| Agile Therapeutics, INC. | $13.24 | 2024 | Twirla |
| Convatec INC. | $13.23 | 2023 | |
| Virtus Pharmaceuticals LLC | $11.77 | 2022 | |
| Medicem INC. | $11.33 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,843,505.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.